WAVE Life Sciences (WVE) saw its stock surge 5.56% intraday on Monday following the release of promising interim data from its Phase 1 trial for WVE-007, an investigational obesity treatment. The results showed significant improvements in body composition, positioning WVE-007 as a potential breakthrough in obesity therapy.

The interim data revealed that a single 240 mg dose of WVE-007 led to a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat, and a 3.2% increase in lean mass at three months. The treatment was also reported to be safe and well-tolerated, with only mild adverse events. These results address a key limitation of existing obesity treatments by preserving muscle mass while reducing fat.

Investors reacted positively to the news, driving the stock higher as the market recognized the potential of WVE-007 as a monotherapy and add-on to incretin therapies. Further clinical updates, including longer-term data, are expected in early 2026.